We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · August 17, 2021

Fast-Acting Insulin Aspart vs Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System

Diabetes Care

 

Additional Info

Diabetes Care
Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System in Adults With Type 1 Diabetes: A Randomized, Open-Label, Crossover Trial
Diabetes Care 2021 Aug 06;[EPub Ahead of Print], MH Lee, B Paldus, S Vogrin, D Morrison, DP Zaharieva, J Lu, HM Jones, E Netzer, L Robinson, B Grosman, A Roy, N Kurtz, GM Ward, RJ MacIsaac, AJ Jenkins, DN O'Neal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading